HETEROGENEITY OF THE EFFECT OF COMBINED FRACTIONATED RADIOTHERAPY AND EGFR/HER2 TYROSINE KINASE INHIBITION

被引：0

作者：

Gurtner, K. ^{[1
,2
]}

Schuetze, C. ^{[1
,2
]}

Soica, F. ^{[3
]}

Baumann, M. ^{[1
,2
]}

Krause, M. ^{[1
,2
]}

机构：

[1] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Fac Med, Dresden, Germany

[2] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Univ Hosp Carl Gustav Carus, Dresden, Germany

[3] Boehringer Ingelheim Austria, Vienna, Austria

来源：

RADIOTHERAPY AND ONCOLOGY | 2008年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

128

引用

页码：S42 / S43

页数：2

共 50 条

[21] HER2 heterogeneity [J].

Prat, A. .

BREAST, 2021, 56 :S4-S4

[22] New dual inhibitors of EGFR and HER2 protein tyrosine kinases [J].

Fink, BE ;

Vite, GD ;

Mastalerz, H ;

Kadow, JF ;

Kim, SH ;

Leavitt, KJ ;

Du, K ;

Crews, D ;

Wong, TW ;

Hunt, JT ;

Vyas, DM ;

Tokarski, JS .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4774-4779

[23] The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches [J].

Zaczek, A ;

Brandt, B ;

Bielawski, KP .

HISTOLOGY AND HISTOPATHOLOGY, 2005, 20 (03) :1005-1015

[24] TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2 [J].

Chouitar, J. ;

Vincent, S. ;

Brake, R. ;

Li, S. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S811-S811

[25] BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy. [J].

Solca, F ;

Baum, A ;

Guth, B ;

Colbatzky, F ;

Blech, S ;

Amelsberg, A ;

Himmelsbach, F .

CLINICAL CANCER RESEARCH, 2005, 11 (24) :9025S-9025S

[26] Pyrrolotriazine dual EGFR/HER2 protein tyrosine kinase inhibitors with solubilizing groups at C-5 [J].

Mastalerz, Harold ;

Chang, Ming ;

Chen, Ping ;

Cook, Donald ;

Dextraze, Pierre ;

Fink, Brian E. ;

Gavai, Ashvinikumar ;

Goyal, Bindu ;

Han, Wen-Ching ;

Johnson, Walter ;

Kim, Soong-Hoon ;

Langley, David ;

Lee, Francis ;

Leavitt, Kenneth ;

Norris, Derek ;

Marathe, Punit ;

Mathur, Arvind ;

Oppenheimer, Simone ;

Ruediger, Edward ;

Tarrant, James ;

Tokarski, John ;

Vite, Gregory ;

Vyas, Dolatrai ;

Wong, Henry ;

Wong, Tai ;

Zhang, Hongjian ;

Zhang, Guifen .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 :806-806

[27] Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition [J].

Yano, S ;

Kondo, K ;

Yamaguchi, M ;

Richmond, G ;

Hutchison, M ;

Wakeling, A ;

Averbuch, S ;

Wadsworth, P .

ANTICANCER RESEARCH, 2003, 23 (5A) :3639-3650

[28] BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations [J].

Yang Chih-Hsin ;

Shih Jin-Yuan ;

Su Wu-Chou ;

Hsia Te-Chun ;

Ho Ching-Liang ;

Dudek, Arkadiusz Z. ;

Terlizzi, Elizabeth ;

Zhao Yihua M ;

Shahidi, Mehdi ;

Miller, Vincent A. .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) :S294-S295

[29] Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition [J].

Yen, Hsin-Yung ;

Liu, Ying-Chih ;

Chen, Nai-Yu ;

Tsai, Chia-Feng ;

Wang, Yi-Ting ;

Chen, Yu-Ju ;

Hsu, Tsui-Ling ;

Yang, Pan-Chyr ;

Wong, Chi-Huey .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (22) :6955-6960

[30] Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification [J].

Meedendorp, Arenda D. ;

ter Elst, Arja ;

't Hart, Nils A. ;

Groen, Harry J. M. ;

Schuuring, Ed ;

van der Wekken, Anthonie J. .

FRONTIERS IN ONCOLOGY, 2018, 8

← 1 2 3 4 5 →